Pfizer Inc.
Cyclic substituted imidazo[4,5-c]quinoline derivatives

Abstract:

The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. ##STR00001##